D.E. Shaw & Co
DFTX

D.E. Shaw & Co’s Definium Therapeutics DFTX Stock Holding History

D.E. Shaw & Co’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.8M Buy
315,410
+43,693
+16% +$1.08M 0.01% 1516
2026
Q1 		$5.14M Sell
271,717
-22,005
-7% -$373K ﹤0.01% 2147
2025
Q4 		$3.93M Buy
293,722
+77,388
+36% +$958K ﹤0.01% 2507
2025
Q3 		$2.55M Buy
216,334
+157,570
+268% +$1.47M ﹤0.01% 2795
2025
Q2 		$381K Sell
58,764
-4,485
-7% -$29.5K ﹤0.01% 3759
2025
Q1 		$370K Buy
+63,249
New +$453K ﹤0.01% 3661
2024
Q2 		– Sell
-183,029
Closed -$1.72M – 4701
2024
Q1 		$1.72M Buy
+183,029
New +$1.04M ﹤0.01% 2741
2022
Q1 		– Sell
-11,147
Closed -$231K – 5796
2021
Q4 		$231K Sell
11,147
-221
-2% -$7.05K ﹤0.01% 4810
2021
Q3 		$397K Buy
11,368
+2,514
+28% +$109K ﹤0.01% 4215
2021
Q2 		$458K Buy
+8,854
New +$465K ﹤0.01% 4078

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

D.E. Shaw & Co's DFTX Position: Q2 2026 in Review

D.E. Shaw & Co increased its Definium Therapeutics (DFTX) stake by 16% in Q2 2026, buying an estimated $1.08M and bringing the position to 315,410 shares worth $14.8M. The position accounts for 0.01% of the portfolio, ranked #1516.

D.E. Shaw & Co first reported a position in DFTX in Q2 2021 and has held it in 10 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • D.E. Shaw & Co held 315,410 shares of Definium Therapeutics worth $14.8M as of Q2 2026.
  • D.E. Shaw & Co bought 43,693 Definium Therapeutics shares in Q2 2026, an estimated $1.08M.
  • Definium Therapeutics made up 0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #1516 holding.
  • D.E. Shaw & Co first reported a position in Definium Therapeutics in Q2 2021 and has held it in 10 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.